12:00 AM
Jul 15, 2013
 |  BC Week In Review  |  Company News  |  Deals

Arch Therapeutics deal

Arch Therapeutics (formerly Almah Inc.) reverse-merged with Arch Biosurgery Inc., with Arch Therapeutics remaining as the surviving entity. The company's AC5 is in preclinical development to achieve hemostasis in minimally invasive and open surgical procedures.

Former Arch Biosurgery shareholders received...

Read the full 182 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >